Search results for CD34 antibody

Anti-CD34 Antibody (R3H58), AntibodySystem, RHD80701

CD34 antibody [QBEND/10], Genetex, GTX73823

CD34 antibody [MEC14.7] (Biotin), Genetex, GTX75410

CD34 antibody [MEC14.7] (FITC), Genetex, GTX75411

CD34 antibody [MEC14.7] (FITC), Genetex, GTX75412

CD34 antibody [MEC14.7] (PE), Genetex, GTX75414

Anti-CD34 antibody [EP373Y], Abcam, AB81289

Anti-CD34 antibody [EP373Y] (ab81289) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), ICC/IF, IHC-Fr, IHC-P and IP. Anti-CD34 antibody [EP373Y] (ab81289) was first used in a scientific publication in 2010 and has been cited over 570 times in peer reviewed journals. It's performance in IHC and Flow Cytometry in human, mouse and rat samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-CD34 antibody [EP373Y] (ab81289) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-CD34 antibody [EP373Y] (ab81289) has 54 independent reviews from customers. Anti-CD34 antibody [EP373Y] (ab81289) specifically detects CD34 (UniProt ID: P28906; Molecular weight: 38kDa) and is sold in 100 µL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone EP373Y - ab188169. Antibody clone EP373Y is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 488, HRP, PE, APC, Alexa Fluor ® 594, Alexa Fluor ® 568, Alexa Fluor ® 555, Alexa Fluor ® 750 ( ab195013 , ab195017 , ab223930 , ab310881 , ab311670 , ab312945 , ab313155 , ab321739 ). CD34 is a marker for hematopoietic stem cells and plays a role in immunology diseases by facilitating cell migration and adhesion, impacting conditions like leukaemia and other hematologic disorders. EP373Y is top cited on the market with over 763 citations and validated in human, mouse, rat samples with the broadest range of applications. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-CD34 antibody [EPR2999], Abcam, AB110643

Species reactivity Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-CD34 antibody [My10], Abcam, AB245689

Anti-CD34 antibody [RM2052], Abcam, AB317588

What are recombinant multiclonals? Recombinant multiclonals are a mixture of recombinant antibodies co-expressed from a library of heavy and light chains. They offer several advantages including: - The sensitivity of polyclonal antibodies by recognising multiple epitopes - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production View our range of recombinant multiclonal antibodies . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents .